139 related articles for article (PubMed ID: 10942238)
21. Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.
Martinez-Lopez J; Martinez-Sanchez P; Garcia-Sanz R; Sarasquete ME; Ayala R; Gonzalez M; Bautista JM; Gonzalez D; San Miguel J; Garcia-Effron G; Lahuerta JJ
J Mol Diagn; 2006 Jul; 8(3):364-70. PubMed ID: 16825510
[TBL] [Abstract][Full Text] [Related]
22. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
Liu JY; Li ZG; Gao C; Cui L; Wu MY
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
[TBL] [Abstract][Full Text] [Related]
23. Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR.
González D; González M; Alonso ME; López-Pérez R; Balanzategui A; Chillón MC; Silva M; García-Sanz R; San Miguel JF
Leukemia; 2003 Jun; 17(6):1051-7. PubMed ID: 12764368
[TBL] [Abstract][Full Text] [Related]
24. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of minimal residual disease in childhood acute lymphoblastic leukaemia.
Yeoh AE; Quah TC; Jeyaseelan K; Lee BW; Poh KS; Sun L
Ann Acad Med Singap; 1997 May; 26(3):365-71. PubMed ID: 9285034
[TBL] [Abstract][Full Text] [Related]
26. Comparison of PCR with southern hybridization for the routine detection of immunoglobulin heavy chain gene rearrangements.
Lehman CM; Sarago C; Nasim S; Comerford J; Karcher DS; Garrett CT
Am J Clin Pathol; 1995 Feb; 103(2):171-6. PubMed ID: 7856559
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
[TBL] [Abstract][Full Text] [Related]
28. Optimal primer selection for clonality assessment by polymerase chain reaction analysis. III. Intermediate and high-grade B-cell neoplasms.
Lombardo JF; Hwang TS; Maiese RL; Millson A; Segal GH
Hum Pathol; 1996 Apr; 27(4):373-80. PubMed ID: 8617481
[TBL] [Abstract][Full Text] [Related]
29. Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas.
Uchiyama M; Maesawa C; Yashima A; Tarusawa M; Satoh T; Ishida Y; Ito S; Murai K; Enomoto S; Utsugisawa T; Motoyoshi K; Masuda T
Cancer Sci; 2003 Oct; 94(10):877-85. PubMed ID: 14556661
[TBL] [Abstract][Full Text] [Related]
30. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
[TBL] [Abstract][Full Text] [Related]
31. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
32. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
33. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
[TBL] [Abstract][Full Text] [Related]
34. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
35. Profile of immunoglobulin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia.
Greenberg SJ; Choi Y; Ballow M; Du TL; Ward PM; Rickert MH; Frankel S; Bernstein SH; Brecher ML
J Leukoc Biol; 1995 Jun; 57(6):856-64. PubMed ID: 7790768
[TBL] [Abstract][Full Text] [Related]
36. Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.
Mayer SP; Giamelli J; Sandoval C; Roach AS; Fevzi Ozkaynak M; Tugal O; Rovera G; Jayabose S
Leukemia; 1999 Nov; 13(11):1843-52. PubMed ID: 10557060
[TBL] [Abstract][Full Text] [Related]
37. [Monitoring IgH levels in patients with B-cell malignancy by real-time quantitative PCR after hematopoietic stem cell transplantation and its significance].
Yu Z; Wang YF; Li ZJ; Zhou Z; Xu SC; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1236-9. PubMed ID: 18088474
[TBL] [Abstract][Full Text] [Related]
38. JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements.
Jenner MJ; Summers KE; Norton AJ; Amess JA; Arch RS; Young BD; Lister TA; Fitzgibbon J; Goff LK
Br J Haematol; 2002 Aug; 118(2):550-8. PubMed ID: 12139744
[TBL] [Abstract][Full Text] [Related]
39. Limitations and practical procedure in BclII-Ig heavy chain gene rearrangement real-time quantitative polymerase chain reaction.
Dessars B; Heimann P; Swillens S; El Housni H
J Mol Diagn; 2006 Feb; 8(1):133-6. PubMed ID: 16436645
[TBL] [Abstract][Full Text] [Related]
40. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies.
Aubin J; Davi F; Nguyen-Salomon F; Leboeuf D; Debert C; Taher M; Valensi F; Canioni D; Brousse N; Varet B
Leukemia; 1995 Mar; 9(3):471-9. PubMed ID: 7533868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
